Floatz logo

Polyiclc

Chronic Myelomonocytic Leukemia

Roswell Park Cancer InstitutePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

83 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Venetoclax
Servier Bio-Innovation LLC
Phase 2/3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Astx727
Taiho Oncology, Inc.
Phase 3BB
Azacitidine
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →